Pharma — April 2023
-
Aktien i Johnson & Johnson steg i tirsdagens eftermarked med 3,1 pct. I den ordinære handel vendte den også et mindre minus til et plus på 1,1 pct.
.\˙ MarketWire
-
Medicinalindustrien trak industriproduktionen op i februar https://www.proinvestor.com/investornyt/964022/medicinalindustrien-trak-industriproduktionen-op-i-februar
-
AstraZeneca : Lynparza Combination Improves PFS In Phase III Ovarian Cancer Trial https://www.proinvestor.com/investornyt/964027/astrazeneca-lynparza-combination-improves-pfs-in-phase-iii-ovarian-cancer-trial
-
Lundbeck/Jefferies: Kursmålet hæves forud for nyt om alzheimershåb -NY https://www.proinvestor.com/investornyt/966430/lundbeck-jefferies-kursmalet-haeves-forud-for-nyt-om-alzheimershab-ny
-
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation https://www.fiercepharma.com/pharma/fda-advisory-committee-backs-lundbeck-and-otsukas-rexulti-use-alzheimers-disease-agitation-9
-
Johnson & Johnson Stock: Bear vs. Bull https://www.proinvestor.com/investornyt/968419/johnson-amp-johnson-stock-bear-vs-bull
-
Merck & Co. agrees to buy Prometheus for $10.8 billion https://firstwordpharma.com/story/5728300
-
+75% i præmie.
-
Lundbeck: Giver FDA panels-ja et kursboost? https://www.proinvestor.com/boards/112071
-
Internationale aviser med Merck, GM og Lloyd's of London https://www.proinvestor.com/investornyt/968636/internationale-aviser-med-merck-gm-og-lloyds-of-london
-
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
https://www.proinvestor.com/investornyt/968639/satsuma-pharma-agrees-to-be-acquired-by-shin-nippon-biomedical -
Genentech : Tecentriq Combination Reduces Risk Of Cancer Returning In People With Liver Cancer https://www.proinvestor.com/investornyt/968640/genentech-tecentriq-combination-reduces-risk-of-cancer-returning-in-people-with-liver-cancer
-
AZN : IMFINZI-based Treatment Reduces Risk Of Disease Recurrence In Lung Cancer In Phase III Trial https://www.proinvestor.com/investornyt/968641/azn-imfinzi-based-treatment-reduces-risk-of-disease-recurrence-in-lung-cancer-in-phase-iii-trial
-
MorphoSys :
Long-term Data Show Prolonged, Durable Responses In DLBCL Patients Treated With Monjuvi https://www.proinvestor.com/investornyt/968633/morphosys-long-term-data-show-prolonged-durable-responses-in-dlbcl-patients-treated-with-monjuvi -
Lundbeck har milliardsællert inden for rækkevidde, vurderer børshus
https://www.proinvestor.com/investornyt/968646/lundbeck-har-milliardsaellert-inden-for-raekkevidde-vurderer-borshus -
GSK Plc: Gepotidacin Shows Non-inferiority To Nitrofurantoin In EAGLE-2 And EAGLE-3 Phase III Trials https://www.proinvestor.com/investornyt/968654/gsk-plc-gepotidacin-shows-non-inferiority-to-nitrofurantoin-in-eagle-2-and-eagle-3-phase-iii-trials
-
Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV https://www.proinvestor.com/investornyt/968741/inovio-presents-data-from-phase-1b-trial-with-ino-4201-as-ebola-booster-for-rvsv-zebov
-
Is Johnson & Johnson a Buy After Its Proposed $8.9 Billion Talc Settlement? https://www.proinvestor.com/investornyt/968764/is-johnson-amp-johnson-a-buy-after-its-proposed-89-billion-talc-settlement
-
Dråbesalg styrker ALK-Abelló på toplinje og drift i første kvartal https://www.proinvestor.com/investornyt/969131/drabesalg-styrker-alk-abello-pa-toplinje-og-drift-i-forste-kvartal
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind